QuantaMatrix, Inc. engages in the research and development, production, and sales of in vitro diagnostic medical devices that utilize substances collected from the human body. It operates through the following divisions: Immunochemical Diagnosis, Self-blood Sugar Test, On-site Diagnosis, Molecular Diagnostics, Blood Test, Clinical Microbiology Diagnosis, Organizational Diagnosis, and Hemostasis Diagnosis. The Immunochemical Diagnosis division is used to diagnose and track a wide variety of diseases. The Self-blood Sugar Test division refers to diabetic patients to self-diagnose blood sugar levels. The On-site Diagnosis division improves treatment effectiveness by enabling immediate testing next to the patient. The Molecular Diagnostics division is involved in testing nucleic acids that contain genetic information of the human body or viruses. The Blood Test division studies blood and bone marrow, used for complete blood count tests and coagulation factor tests. The Clinical Microbiology Diagnosis division examines the body fluids of patients suspected of having various microbial infections to determine whether or not there is an actual infection by a specific microorganism. The Organizational Diagnosis division focuses on cancerous tissue or cells by smearing body fluids on a glass plate or staining living tissue and then analyzing it through a microscope. The Hemostasis Diagnosis division tests necessary for diagnosing various blood diseases, such as tests related to bleeding and thrombosis. The company was founded by Sung-Hoon Kwon on November 29, 2010 and is headquartered in Seoul, South Korea.